In April 2026, Nora Volkow and Xu reviewed reports of lower rates of alcohol-related events, reduced opioid overdose risk, and associations extending to nicotine, cocaine, cannabis, and other substances
Most big pharma companies have at least one amylin in development, the most advanced of which is Novo Nordisks CagriSema, a dual amylin/GLP-1 agonist currently under FDA review
If maintaining that natural pulse is your priority and you would like to preserve long-term receptor sensitivity, then the shorter-acting peptide variant is right for you, even if it means more frequent injections
This guide explains the real differences between Zepbound and Wegovy using simple language, real world examples, and clear comparisons to help you understand which option may fit your goals better